Literature DB >> 10612714

Hydrolysis of phospholipids by purified milk lipoprotein lipase. Effect of apoprotein CII, CIII, A and E, and synthetic fragments.

D A Lambert1, L C Smith, H Pownall, J T Sparrow, J P Nicolas, A M Gotto.   

Abstract

Different pyrene-labeled phospholipid monolayer vesicles were used as substrates for the bovine milk lipoprotein lipase activity. The effects of synthetic fragments of apoprotein C II were measured on the hydrolysis of 1-myristoyl-2[9(1pyrenyl)-nonanoyl] phosphatidylcholine in vesicles: The activating capacity of fragments 30-78 and 43-78, 50-78 and 55-78, compared to entire apo CII, were similar to that obtained with hydrolysable triglycerides. Our study shows that the longer the carboxy terminal fragment is, the higher is the activation. The phospholipid hydrolysis activity represents in the presence of apo C II, 36% of the triglycerides hydrolysis activity. Phospholipid hydrolysis is less dependent on activator than triglycerides hydrolysis (100% and 300% of increase with apo CII for phosphatidyl-choline and triglycerides respectively). The ratio hydrolysis without apo C II/hydrolysis with apo CII was different when other phospholipids than myrystoyl-phospatidylcholine were assayed: phosphatidyl-serine, ethanolamine, -choline, -glycerol, or diglycerides and butanoylglycerols. Fragment CIII(1) (1-40) which did not bind to lipids, had no inhibitory effect. The entire sugar moiety and the first 40 amino acids are not required for the total inhibition of LPL. Inhibition was also obtained with Apo A I, A II,C I and fragments of apo E.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10612714     DOI: 10.1016/s0009-8981(99)00193-x

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  5 in total

Review 1.  Apolipoproteins in vascular biology and atherosclerotic disease.

Authors:  Anurag Mehta; Michael D Shapiro
Journal:  Nat Rev Cardiol       Date:  2021-10-08       Impact factor: 32.419

Review 2.  Emerging Evidence that ApoC-III Inhibitors Provide Novel Options to Reduce the Residual CVD.

Authors:  Marja-Riitta Taskinen; Chris J Packard; Jan Borén
Journal:  Curr Atheroscler Rep       Date:  2019-05-20       Impact factor: 5.113

Review 3.  Apolipoprotein CIII Is an Important Piece in the Type-1 Diabetes Jigsaw Puzzle.

Authors:  Ismael Valladolid-Acebes; Per-Olof Berggren; Lisa Juntti-Berggren
Journal:  Int J Mol Sci       Date:  2021-01-19       Impact factor: 5.923

Review 4.  Why Is Apolipoprotein CIII Emerging as a Novel Therapeutic Target to Reduce the Burden of Cardiovascular Disease?

Authors:  Marja-Riitta Taskinen; Jan Borén
Journal:  Curr Atheroscler Rep       Date:  2016-10       Impact factor: 5.113

Review 5.  The Roles of ApoC-III on the Metabolism of Triglyceride-Rich Lipoproteins in Humans.

Authors:  Jan Borén; Chris J Packard; Marja-Riitta Taskinen
Journal:  Front Endocrinol (Lausanne)       Date:  2020-07-28       Impact factor: 5.555

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.